Literature DB >> 3411438

Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers.

J Fujii1, N Inotsume, M Nakano.   

Abstract

The extent of bioavailability of midazolam following sublingual and oral administration were evaluated. Three healthy volunteers received a single 15-mg dose of midazolam maleate by sublingual and oral routes on two occasions in a ossover design. Concentrations of midazolam in plasma during 4 h after each dose were measured by gas-liquid chromatography with an electron-capture detector. The mean AUC0-4 value following sublingual administration was significantly greater than that following oral administration (14889 vs 3594 ng. min/ml, p less than 0.05). The peak plasma concentration after sublingual dose was also significantly higher than that after oral administration (p less than 0.05). The mean AUC0-4 value of midazolam after sublingual administration was increased four times compared with that after oral administration, possibly due to avoidance of first-pass effect. Thus, the clinical effects of midazolam may likewise be enhanced by sublingual administration of midazolam.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411438     DOI: 10.1248/bpb1978.11.206

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  3 in total

1.  Development of midazolam sublingual tablets: in vitro study.

Authors:  P Odou; C Barthelemy; H Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 2.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Pharmacokinetics of midazolam: comparison of sublingual and intravenous routes in rabbit.

Authors:  P Odou; C Barthélémy; D Chatelier; M Luyckx; C Brunet; T Dine; B Gressier; M Cazin; J C Cazin; H Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.